5th Annual Pre-Filled Syringes & Injectables SummitWelcome to the 5th anniversary edition of the Pre-Filled Syringes & Injectables Summit on September 18-19, 2019, in Share X5th Annual Pre-Filled Syringes & Injectables Summithttps://pharmaphorum.com/partner-content/5th-annual-pre-filled-syringes-injectables-summit/
NICE backs funding for MSD’s diabetes drug SteglatroNICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro Share XNICE backs funding for MSD’s diabetes drug Steglatrohttps://pharmaphorum.com/news/nice-backs-funding-for-msds-diabetes-drug-steglatro/
Health secretary hints at ‘constructive’ talks over CF drugsHealth secretary Matt Hancock has offered hope to thousands of people in the UK who have been denied Share XHealth secretary hints at ‘constructive’ talks over CF drugshttps://pharmaphorum.com/news/health-secretary-hancock-hints-at-constructive-talks-vertex/
Market access roundup: Government grillings for Vertex and US pharmaIt was a month characterised by governments butting heads with pharma over pricing both in the UK and Share XMarket access roundup: Government grillings for Vertex and US pharmahttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-government-grillings-vertex-us-pharma-pricing/
UK politicians to grill Vertex CEO over CF price drug rowThe CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating Share XUK politicians to grill Vertex CEO over CF price drug rowhttps://pharmaphorum.com/news/uk-politicians-to-grill-vertex-ceo-over-cf-price-drug-row/
Catalyst defends huge US price hike for rare disease drugCatalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to Share XCatalyst defends huge US price hike for rare disease drughttps://pharmaphorum.com/news/catalyst-defends-huge-us-price-hike-for-rare-disease-drug/
Catalyst sparks price row in US with $300,000 rare disease drugThe controversy over rising drug prices in the US has been reignited after it emerged that the yearly Share XCatalyst sparks price row in US with $300,000 rare disease drughttps://pharmaphorum.com/news/catalyst-sparks-price-row-in-us-with-300000-rare-disease-drug/
Novartis and Lilly CEOs back Trump plans to cut drug pricesCEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health Share XNovartis and Lilly CEOs back Trump plans to cut drug priceshttps://pharmaphorum.com/news/novartis-and-lilly-ceos-back-trump-plans-to-cut-drug-prices/
Brexit could hinder CAR-T reimbursement in EuropeBrexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, Share XBrexit could hinder CAR-T reimbursement in Europehttps://pharmaphorum.com/news/brexit-could-hinder-car-t-reimbursement-in-europe/
